2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1709

Classical Monocytes in the Pathogenesis of Early Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 47

Claudin-11 Regulates Bone Homeostasis Via Bidirectional EphB4-EphrinB2 Signaling
Abstract Number: 490

Clinical and Biomarker Factors in the Prediction of Future Inflammatory Arthritis in ACPA Positive Subjects without Inflammatory Arthritis at Baseline
Abstract Number: 1497

Clinical and Laboratory Features of Patients with Focal Lymphocytic Sialadenitis on Minor Salivary Gland Biopsy for Sicca Symptoms: A 16 Year Experience
Abstract Number: 946

Clinical and Serological Features of Systemic Sclerosis in a Multicenter African American Cohort: Analysis of the Genome Research in African American Scleroderma Patients Clinical Database
Abstract Number: 639

Clinical and Sonographic Analysis of Patients with Psoriasis without Musculoskeletal Complaints. Preeliminary Results of a Prospective Study: The PRE-Psa Cohort
Abstract Number: 520

Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-up Dosing of Tofacitinib in a Treat to Target Approach
Abstract Number: 2035

Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases
Abstract Number: 1513

Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Abstract Number: 2733

Clinical Characteristics and Treatment Outcomes of Patients with Behçet’s Disease and Vascular Involvement
Abstract Number: 1161

Clinical Characteristics of Ocular Sarcoidosis: A Population Based Study 1976-2013
Abstract Number: 1165

Clinical Characteristics of Patients with Late-Onset Familial Mediterranean Fever in Japan
Abstract Number: 2133

Clinical Characteristics of the Patients with Recurrent Myositis in Polymyositis and Dermatomyositis: A Retrospective Study
Abstract Number: 2939

Clinical Correlate of Synovial Proliferation in Early Rheumatoid Arthritis
Abstract Number: 2880

Clinical Evolution of Patients with Inflammatory Back Pain: A Population-Based Longitudinal Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].